Introduction {#s1}
============

Migraine is an episodic brain disorder that affects 15% of general population.^[@R1]^ It is one of the very common referral to neurology clinic, highly disabling, costly and difficult to treat. Two types of treatment are available of which one is the treatment of acute attack. Another is for prophylaxis. Non specific treatment for acute attack includes aspirin, paracetamol, naproxen, ibuprofen, tolfenamic acid with or without antiemetic agents. Many patients suffer from 2 or more migraine attacks per month. Taking non specific analgesic more than 10 days per month can also produce drug induced headache. Moreover such drugs can also produce gastrointestinal (GI) intolerance. Specific treatments for migraine include ergotamine and triptans. Ergatoamine is known to have higher incidence of nausea than triptans, however, its overuse can produce dreadful headache besides various vascular problems.

Triptans are very effective in acute migraine attack. Their pharmacokinetic features are excellent.^[@R2]^ There are very few studies depicting efficacy, tolerability and side effects of zolmitriptan in acute migraine attack.

Methods {#s2}
=======

Our study group consisted of 137 migraine patients from Neurology out door of Calcutta National Medical College and Hospital. Migraine diagnosis was confirmed by neurology according to simplified diagnostic criteria established for migraine adapted from the Headache Classification Committee of the International Headache Society 2004.^[@R3]^

Those patients suffering from more than 3 months and having 2 or more attacks per month were recruited for this study and their headache and other symptom severity were assessed by visual analogue scale.^[@R4]^

  ------------------------------- -------------------
  At least 2 of                   At least 1 of
  Unilateral pain                 Nausea / vomiting
  Throbbing pain                  Photophobia
  Aggravation by movement         Phonophobia
  Moderate and severe intensity    
  ------------------------------- -------------------

Repeated attack of headache lasting 4-72 hour that have these features, normal physical examination and no other reasonable cause of headache. Ethical approval was obtained.

Demographic characteristic, symptoms incidence and number of attack per month before treatment of the study group are shown in [table 1](#tbl_1){ref-type="table"}, [2](#tbl_2){ref-type="table"}, [3](#tbl_3){ref-type="table"} respectively.

Those patients were excluded from the study that presented with hypertension ischemic heart disease, complicated migraine and multiple risk factors for coronary vascular disease, pregnancy and nursing mothers. All patients were given prophylactic drugs if migraine attacks were more than 2 per month or episodes were disabling for more than 2 days. Zolmitriptan nasal spray was given within 6-8 hour of migraine attack when pain was moderate to severe headache. The dose was repeated after 2 hours if it was partially effective.

###### Demographic characteristics of study group

  ---------------------------- ------------
  Male                         35 (27%)
  Female                       95 (73%)
  Age                          4-50 years
  Family history of migraine   91 (70%)
  Migraine with aura           26 (20%)
  ---------------------------- ------------

###### Profile of clinical symptoms

  ------------------- -----------
  Photophobia         111 (86%)
  Phonophobia         104 (80%)
  Nausea / Vomiting   117 (90%)
  Disability          117 (90%)
  ------------------- -----------

###### No. of migraine attacks per month

  No of attacks   Percentage
  --------------- ------------
  2               20%
  3               18%
  4               15%
  5 or more       30%

One spray is equivalent to 5 mg of zolmitriptan. Repeat VAS scoring was done every 1 hour and change of symptoms was analyzed. 2^nd^ dose of nasal spray was given if there was partial improvement of headache. Maximum dose did not exceed 2 days/week. There were 7 patients that required withdrawal of drug due to high cost and side effects.

Results {#s3}
=======

Improvement of headache and other various symptoms associated with it including photophobia, phonophobia, nausea and disability were assessed and motor side effects recorded. Headache was found to be relieved completely in 60%, partially in 25%, photophobia completely in 60%, partially in 20%. Phonophobia was found to be relieved completely in 50%, partially in 35%. Nausea was found to be completely relieved in 80%, partially in 15%. Similarly, disability was found to be completely resolved in 75%, partially in 15%. In 80% of patient's headache improved within one hour. Recurrence within 24 hours was upto 30%, rebound headache of upto 30% and consistency (no recurrence within 24 hours) in 60% cases. 2^nd^ dose of zolmitriptan did not improve symptoms further. Side effects included flushed sensation in 30% cases. Sensation of chest pressure was seen in 10%, with paresthesia in 10% and dizziness and weakness upto 20% while 5% patients required withdrawal of drugs due to side effects. We did not find any significant difference in migraine presenting with aura or without aura.

Discussion {#s4}
==========

Trigemino vascular system has a prominent role in migraine attack.^[@R5]^ It has been reported that there is sterile inflammation due to release of neuropeptides like calcitonin gene related peptides (GRP Neurokin A and Substance P)^[@R6]^ that could be involved in the pathophysiology of migraine.

###### Symptoms relieved rate (%)

  Symptoms      Complete   Partial   No
  ------------- ---------- --------- -----
  Headache      60%        15%       25%
  Photophobia   60%        20%       20%
  Phonophobia   50%        35%       15%
  Nausea        80%        15%       5%
  Disability    75%        15%       10%

###### Side effects of Zolmitriptan nasal spray

  ----------------------------- -----
  Flushed sensation             30%
  Sensation of chest pressure   10%
  Paresthesia                   10%
  Dizziness & weakness          20%
  Unpleasant taste              30%
  ----------------------------- -----

Triptans exert their treatment effects through presynaptic inhibition of peripheral trigemino vascular neurons (5HT~1B~) and through central action on trigemino nociceptive pathways (5HT~1D~).^[@R7]^ Blocking of the calcium gene related peptide (CGRP) and vasoconstriction are also possible mechanism of action of Triptans.^[@R8]^ Many patients have severe digestive symptoms precluding oral drug intake and a formulation of intranasal triptan has shown good efficacy.^[@R9]^ There are a few studies comparing efficacy of different type of triptans.^[@R10]^ Almotriptan at 12.5 mg was found to be effective for menstrually related migraine producing 48.4% pain free state and 2-24 hr of sustained pain free state in most patients.^[@R11]^ Rizatriptan at 10 mg was found to be effective producing 51% pain relief rate for 2 hr and 22% pain freedom with a sustained pain relief rate of 38% as well as good tolerance.

Our study found that zolmitriptan nasal spray not only reduces headache (85%) but it also reduces other symptoms of migraine like photophobia, phonophobia, nausea and disability (80-90%) of patient and with mild side effects like unpleasant test, flushed sensation, chest pressure dizziness (10-30%). 2^nd^ dose of zolmitriptan nasal spray was not found to improve headache and other symptoms much.

Limitations {#s5}
===========

This is not a double blind, randomized, controlled clinical trial. It is not a comparative study with other triptans. Comparing efficacy in gender and age groups has not been conducted here.
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